FLORENCE, Italy, May 22, 2016 /PRNewswire/--ResMed (NYSE: RMD) today announced primary results from a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European ...

Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...

In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV ...

Breathing machines with adaptive servo-ventilation (ASV) did not improve survival or other clinical outcomes in patients with heart failure (HF) and reduced ejection fraction and sleep-disordered ...

SAN DIEGO, May 13, 2015 /PRNewswire/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.

Michael Arzt, MD, investigated the use of ASV therapy in patients with TE-CSA and cardiovascular disease, finding it effective in reducing sleepiness and improving quality of life. It may be more ...

Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnoea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.

ATS 2016, SAN FRANCISCO -- Chronic heart failure (CHF) patients with predominant central sleep apnea (CSA) are at higher risk for death and unplanned hospitalization than those who have both CSA and ...

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...